Marshall Wace’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $231K | Sell |
1,061
-648,939
| -100% | -$144M | ﹤0.01% | 2728 |
|
|
2025
Q4 | $149M | Sell |
650,000
-627,167
| -49% | -$143M | 0.14% | 123 |
|
|
2025
Q3 | $296M | Sell |
1,277,167
-102,168
| -7% | -$20.8M | 0.3% | 41 |
|
|
2025
Q2 | $256M | Buy |
1,379,335
+1,137,548
| +470% | +$211M | 0.29% | 54 |
|
|
2025
Q1 | $50.7M | Sell |
241,787
-1,335,108
| -85% | -$260M | 0.06% | 265 |
|
|
2024
Q4 | $280M | Buy |
1,576,895
+247,726
| +19% | +$45.5M | 0.34% | 41 |
|
|
2024
Q3 | $262M | Buy |
1,329,169
+443,254
| +50% | +$82.7M | 0.32% | 45 |
|
|
2024
Q2 | $152M | Sell |
885,915
-791,353
| -47% | -$131M | 0.2% | 88 |
|
|
2024
Q1 | $305M | Sell |
1,677,268
-1,495,772
| -47% | -$258M | 0.47% | 29 |
|
|
2023
Q4 | $492M | Sell |
3,173,040
-733,450
| -19% | -$107M | 0.83% | 11 |
|
|
2023
Q3 | $582M | Buy |
3,906,490
+3,004,224
| +333% | +$441M | 1.18% | 9 |
|
|
2023
Q2 | $122M | Buy |
902,266
+121,471
| +16% | +$17.8M | 0.24% | 81 |
|
|
2023
Q1 | $124M | Buy |
780,795
+763,796
| +4,493% | +$117M | 0.26% | 76 |
|
|
2022
Q4 | $2.75M | Sell |
16,999
-29,179
| -63% | -$4.47M | 0.01% | 1550 |
|
|
2022
Q3 | $6.2M | Sell |
46,178
-375,414
| -89% | -$53.9M | 0.01% | 1212 |
|
|
2022
Q2 | $64.6M | Sell |
421,592
-778,337
| -65% | -$119M | 0.13% | 152 |
|
|
2022
Q1 | $195M | Buy |
1,199,929
+886,248
| +283% | +$129M | 0.37% | 43 |
|
|
2021
Q4 | $42.5M | Buy |
313,681
+284,278
| +967% | +$33.6M | 0.08% | 256 |
|
|
2021
Q3 | $3.17M | Buy |
29,403
+24,568
| +508% | +$2.81M | 0.01% | 1223 |
|
|
2021
Q2 | $545K | Sell |
4,835
-171,309
| -97% | -$19.3M | ﹤0.01% | 2089 |
|
|
2021
Q1 | $19.1M | Sell |
176,144
-105,571
| -37% | -$11.3M | 0.09% | 235 |
|
|
2020
Q4 | $30.2M | Sell |
281,715
-235,438
| -46% | -$22.6M | 0.16% | 125 |
|
|
2020
Q3 | $45.3M | Sell |
517,153
-772,167
| -60% | -$72.7M | 0.29% | 77 |
|
|
2020
Q2 | $127M | Buy |
1,289,320
+704,319
| +120% | +$62M | 0.89% | 18 |
|
|
2020
Q1 | $44.6M | Buy |
585,001
+499,540
| +585% | +$42.5M | 0.45% | 43 |
|
|
2019
Q4 | $7.57M | Buy |
85,461
+25,182
| +42% | +$2.09M | 0.05% | 387 |
|
|
2019
Q3 | $4.56M | Sell |
60,279
-43,693
| -42% | -$3M | 0.04% | 533 |
|
|
2019
Q2 | $7.56M | Buy |
103,972
+74,484
| +253% | +$5.85M | 0.06% | 361 |
|
|
2019
Q1 | $2.38M | Sell |
29,488
-230,525
| -89% | -$18.9M | 0.02% | 688 |
|
|
2018
Q4 | $24M | Buy |
+260,013
| New | +$22.9M | 0.24% | 84 |
|
|
2017
Q2 | – | Sell |
-14,914
| Closed | -$969K | – | 301 |
|
|
2017
Q1 | $969K | Buy |
+14,914
| New | +$938K | 0.05% | 206 |
|
|
2016
Q3 | – | Sell |
-11,479
| Closed | -$711K | – | 919 |
|
|
2016
Q2 | $711K | Sell |
11,479
-21,490
| -65% | -$1.31M | 0.01% | 767 |
|
|
2016
Q1 | $1.88M | Sell |
32,969
-10,458
| -24% | -$583K | 0.02% | 574 |
|
|
2015
Q4 | $2.57M | Buy |
43,427
+6,828
| +19% | +$393K | 0.02% | 509 |
|
|
2015
Q3 | $1.99M | Sell |
36,599
-900
| -2% | -$58.6K | 0.02% | 458 |
|
|
2015
Q2 | $2.52M | Sell |
37,499
-91,362
| -71% | -$5.96M | 0.03% | 420 |
|
|
2015
Q1 | $7.54M | Buy |
+128,861
| New | +$7.78M | 0.1% | 245 |
|
|
2014
Q4 | – | Sell |
-59,691
| Closed | -$3.45M | – | 787 |
|
|
2014
Q3 | $3.45M | Buy |
+59,691
| New | +$3.31M | 0.05% | 347 |
|
Other funds holding ABBV
VCM
VPM
Marshall Wace's ABBV Position: Q1 2026 in Review
Marshall Wace reduced its AbbVie (ABBV) stake by 100% in Q1 2026, selling an estimated $144M and leaving 1,061 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #2728.
Marshall Wace first reported a position in ABBV in Q3 2014 and has held it in 38 quarters since. The position peaked at $582M in Q3 2023. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Marshall Wace held 1,061 shares of AbbVie worth $231K as of Q1 2026.
- Marshall Wace sold 648,939 AbbVie shares in Q1 2026, an estimated $144M.
- AbbVie made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2728 holding.
- Marshall Wace first reported a position in AbbVie in Q3 2014 and has held it in 38 quarters since.
- Marshall Wace's AbbVie position peaked at $582M in Q3 2023.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.